



UvA-DARE (Digital Academic Repository)

Enzyme replacement therapy in Fabry disease, towards individualized treatment

Arends, M.

Publication date

2017

Document Version

Other version

License

Other

[Link to publication](#)

Citation for published version (APA):


Arends, M. (2017). *Enzyme replacement therapy in Fabry disease, towards individualized treatment*. [Thesis, fully internal, Universiteit van Amsterdam].

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.



Enzyme replacement therapy in Fabry disease, towards individualized treatment

Maarten Arends

Enzyme replacement therapy in Fabry disease, towards individualized treatment

Maarten Arends

COLOFON

Enzyme replacement therapy in Fabry disease, towards individualized treatment

Dissertation, University of Amsterdam, the Netherlands

© Maarten Arends, 2017

All rights reserved. No part of this publication may be reproduced or transmitted by any means, without written permission of the author.

Financial support for the printing of this thesis was kindly provided by the Academic Medical Center, Gaucher Stichting, Hartstichting and Nierstichting.

ISBN	978-94-028-0702-8
Author	Maarten Arends
Cover	Structural formula of α -galactosidase A
Design	Liske van der Vliet (persoonlijkproefschrift.nl)
Printing	Ipskamp Printing (www.proefschriften.net)

Enzyme replacement therapy in Fabry disease, towards individualized treatment

ACADEMISCH PROEFSCHRIFT

ter verkrijging van de graad van doctor

aan de Universiteit van Amsterdam

op gezag van de Rector Magnificus

prof. dr. ir. K.I.J. Maex

ten overstaan van een door het College voor Promoties ingestelde commissie,

in het openbaar te verdedigen in de Agnietenkapel

op woensdag 15 november 2017, te 14:00 uur

door Maarten Arends

geboren te Alkmaar

Promotiecommissie

Promotor	Prof. dr. C.E.M. Hollak	AMC - UVA
Copromotor	Dr. M. Biegstraaten	AMC - UVA
Overige leden	Prof. dr. Y.M. Smulders	Vrije Universiteit Amsterdam
	Prof. dr. H.R. Waterham	AMC - UVA
	Prof. dr. A.A.M. Wilde	AMC - UVA
	Prof. dr. A.H. Zwinderman	AMC - UVA
	Dr. R.H. Lachmann	University College London
	Dr. G.E. Linthorst	AMC - UVA

Faculteit der Geneeskunde

Contents

1	General introduction	7
2	Quality of life in patients with Fabry disease: a systematic review of the literature	23
3	Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study	51
4	Characterization of classical and non-classical Fabry disease: a large multicenter cohort study	73
5	Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors	105
6	Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study	133
7	Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in male classical Fabry patients	163
8	Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort	183
9	Summary and general discussion	199
Appendix	Nederlandse samenvatting	221
	Contributing authors	225
	Financial support	227
	PhD portofolio	229
	Dankwoord	233